MediGene Concludes Agreement with Juste for the Commercialization of Veregen in Spain and Portugal

MediGene to receive milestone payments totalling up to 2,550,000 euro and royalties on future sales

25-Jun-2009 - Portugal

MediGene AG has entered into a marketing partnership with the Spanish company Juste S.A.Q.F. for the commercialization of Veregen® ointment (formerly Polyphenon E®) in Spain and Portugal. Juste will promote and distribute the drug for the treatment of genital warts. Depending on specified milestones and sales targets achieved, MediGene is entitled to successive payments totalling up to 2,550,000 euro. MediGene will supply Juste with the finished product, and will receive royalties on the sales revenue for Veregen®.

Veregen® is currently undergoing a decentralized procedure in Germany, Austria, and Spain, and conclusion of this process is expected soon. Thereafter, MediGene is planning to apply for approval in further European countries. MediGene intends to conclude additional marketing agreements for countries in and outside Europe.

Other news from the department business & finance

More news from our other portals

All FT-IR spectrometer manufacturers at a glance